Rallybio (RLYB) said Tuesday that the European Medicines Agency and the UK's Medicines and Healthcare products Regulatory Agency approved its applications for a phase 2 study of RLYB212 in pregnant women at higher risk of developing HPA-1a alloimmunization, which can lead to fetal and neonatal alloimmune thrombocytopenia.
With the approvals, the company said it intends to initiate screening of participants in Q4.
Rallybio said the phase 2 dose confirmation study will evaluate the safety and pharmacokinetics of RLYB212 in a total of eight pregnant women in Belgium, the Netherlands, Norway, Sweden, and the UK.
Shares of the company were up 1.9% in recent Tuesday trading.
Price: 1.06, Change: +0.02, Percent Change: +1.92
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。